secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001140361-24-014239
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys: 24% pregnancy rate with FemaSeed in severe male factor infertility trial, more than triple IUI rate
--------------------------------------------------------------------------------

- Pivotal trial: 24% of women became pregnant after FemaSeed in severe male factor (TMSC 1M-20M), vs 6.7% per cycle for IUI in literature.
- Majority of successful pregnancies required only one FemaSeed procedure.
- No new safety concerns; adverse events mild and consistent with known IUI events.
- FDA clearance obtained September 2023; commercial launch planned first half of 2024.
- Capital infusion at end of 2023 provides funding into second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/0001140361-24-014239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/ef20024684_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-014239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer